Research programme: ATRN protein inhibitors - Atrin Pharmaceuticals
Alternative Names: APRE-DDRI - Aprea Therapeutics; Ataxia telangiectasia and Rad3-related protein inhibitors - Atrin Pharmaceuticals; ATRN 502; ATRN 507; ATRN-212Latest Information Update: 26 Jun 2023
At a glance
- Originator Atrin Pharmaceuticals
- Developer Atrin Pharmaceuticals; University of Pennsylvania
- Class Small molecules
- Mechanism of Action DNA repair inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Jun 2023 Preclinical development is ongoing in Solid tumours in USA (Aprea Therapeutics pipeline, June 2023)
- 23 Jun 2023 Research programme: ATRN protein inhibitors - Atrin Pharmaceuticals is available for licensing as of 23 Jun 2023. https://www.aprea.com/partnering/ (Aprea website, June 2023)
- 16 May 2022 Atrin Pharmaceuticals has been acquired by Aprea